Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva transition study in moderate to severe chronic plaque psoriasis
2007-004243-29Phase 4Terminated
- Sponsor
- Merck Serono
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efalizumab in psoriasis, sponsored by Merck Serono. Primary endpoint: Safety. Started May 2008; status: terminated.
02
Drugs
efalizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2007-004243-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004243-29.